Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase
Authors:
- Michael ChoMCMichael Cho
- Yate-Ching YuanYYYate-Ching Yuan
- Shiuan ChenSCShiuan Chen
- 1 March 2008
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 75 (5) , 1161-1169
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Structure–function studies of aromatase and its inhibitors: a progress reportThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Study of substrate specificity of human aromatase by site directed mutagenesisEuropean Journal of Biochemistry, 2002
- Evaluation of the mechanism of aromatase cytochrome P450European Journal of Biochemistry, 2001
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- A three‐dimensional model of aromatase cytochrome P450Protein Science, 1995
- ARIMIDEX™: A new oral, once-a-day aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancerCancer, 1995